Efficacy and safety of every-2-weeks cetuximab combined with FOLFOX or FOLFIRI as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (mCRC): An Asia-Pacific nonrandomized phase II study (APEC).

被引：0

作者：

Cheng, Ann-Lii

Cornelio, Gerardo H.

Shen, Lin

Price, Timothy Jay

Yang, Tsai-Shen

Chung, Ik-Joo

Dai, Guanghai

Lin, Jen-Kou

Sharma, Atul

Yeh, Kun-Huei

Ma, Brigette

Zaatar, Adel

Guan, Zhongzhen

Masood, Nehal

Srimuninnimit, Vichien

Yau, Thomas Cheung

Sarholz, Barbara

Lim, Robert S. C.

机构：

[1] Natl Taiwan Univ Hosp, Taipei, Taiwan

[2] San Juan De Dios Hosp, Pasay City, Philippines

[3] Peking Univ, Canc Hosp, Minist Educ, Dept Gastrointestinal Oncol,Key Lab Carcinogenesi, Beijing 100871, Peoples R China

[4] Queen Elizabeth Hosp, Adelaide, SA, Australia

[5] Chang Gung Mem Hosp, Taoyuan, Taiwan

[6] Chonnam Natl Univ, Hawsun Hosp, Hwasuneup, South Korea

[7] Peoples Liberat Army, Gen Hosp, Beijing, Peoples R China

[8] Taipei Vet Gen Hosp, Taipei, Taiwan

[9] All India Inst Med Sci, New Delhi, India

[10] Chinese Univ Hong Kong, Prince Wales Hosp, Sha Tin, Hong Kong, Peoples R China

[11] Mt Miriam Canc Hosp, George Town, Malaysia

[12] Sun Yat Sen Univ, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China

[13] Aga Khan Univ & Hosp, Karachi, Pakistan

[14] Siriraj Hosp, Bangkok, Thailand

[15] Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China

[16] Merck KGaA, Darmstadt, Germany

[17] Natl Univ Hlth Syst, Singapore, Singapore

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e14501

引用

页数：1

共 50 条

[41] COMPARISON OF FOLFOX6 PLUS CETUXIMAB WITH FOLFIRI PLUS CETUXIMAB AS FIRST-LINE THERAPY IN METASTATIC COLORECTAL CANCER (MCRC): A RANDOMIZED OPEN-LABEL PHASE II CECOG STUDY
Beslija, S.
Koza, I.
Ocvirk, J.
Ciuleanu, T.
Kurteva, G.
Papamichael, D.
Vrbanec, D.
Messinger, D.
Brodowicz, T.
Zielinski, C. C.
ANNALS OF ONCOLOGY, 2008, 19 : 168 - 168
[42] Prognostic genomic signatures in patients with RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) from the phase III study of first-line FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone (ERMES study).
Normanno, Nicola
Rachiglio, Anna Maria
Abate, Riziero Esposito
Orlandi, Armando
Maiello, Evaristo
Maglietta, Giuseppe
Damato, Angela
Maiello, Monica Rosaria
Carotenuto, Marianeve
Calegari, Maria Alessandra
Antonuzzo, Lorenzo
Bordonaro, Roberto
Zampino, Maria Giulia
Tamberi, Stefano
Lonardi, Sara
Avallone, Antonio
Latiano, Tiziana Pia
Tamburini, Emiliano
Barone, Carlo Antonio
Pinto, Carmine
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[43] Association between early tumour shrinkage (ETS) and outcomes in RAS-wild type (WT) patients (pts) with metastatic colorectal cancer (mCRC) receiving first-line FOLFOX or FOLFIRI plus cetuximab every other week in the APEC study
Cheng, A. -L.
Cornelio, G. H.
Shen, L.
Prince, T. J.
Yang, T. -S.
Chung, I. -J.
Dai, G.
Lin, J. -K.
Sharma, A.
Yeh, K. -H.
Ma, B.
Zaatar, A.
Guan, Z.
Masood, N.
Srimuninnimit, V.
Yau, T. Cheung
Beier, F.
Chatterjee, S.
Lim, R. S. C.
ANNALS OF ONCOLOGY, 2015, 26 : 45 - 46
[44] Cost-minimization analysis of biweekly dosing of cetuximab and FOLFIRI compared with panitumumab and FOLFOX for first-line treatment of patients with KRAS wild-type metastatic colorectal cancer in the United States
Gathirua-Mwangi, Wambui Grace
Sethi, Harsheen
Afable, Manuel Geroy
Bhattacharyya, Devarshi
Khan, Taha
JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 1164 - 1172
[45] Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients
Stintzing, S.
Jung, A.
Rossius, L.
Modest, D. P.
von Weikersthal, L. Fischer
Decker, T.
Moehler, M.
Scheithauer, W.
Kirchner, T.
Heinemann, V.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S8 - S9
[46] Correlation of KRAS status (wild type [wt] vs. mutant [mt]) with efficacy to first-line cetuximab in a study of cetuximab single agent followed by cetuximab plus FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC)
Cervantes, A.
Macarulla, T.
Martinelli, E.
Rodriguez-Braun, E.
Ciardiello, F.
Stroh, C.
Nippgen, J.
Baselga, J.
Tabernero, J.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[47] COST-EFFECTIVENESS OF CETUXIMAB AND BEVACIZUMAB IN THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC) FOR PATIENTS WITH KRAS WILD-TYPE TUMOURS IN THE UNITED KINGDOM
Samyshkin, Y.
Hertel, N.
Griebsch, I
VALUE IN HEALTH, 2011, 14 (07) : A446 - A447
[48] Cost-Effectiveness of Cetuximab and Bevacizumab in the First-Line Treatment of Metastatic Colorectal Cancer (mCRC) for Patients With KRas Wild-Type Tumours in the United Kingdom
Samyshkin, Y.
Hertel, N.
Griebsch, I.
EUROPEAN JOURNAL OF CANCER, 2011, 47 : S264 - S264
[49] Prognostic role of TP53 variants in the phase III study of FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of patients with RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) (ERMES study)
Normanno, Nicola
Orlandi, Armando
Maiello, Evaristo
Rachiglio, Anna Maria
Maglietta, Giuseppe
Damato, Angela
Calegari, Maria Alessandra
Antonuzzo, Lorenzo
Bordonaro, Roberto
Zampino, Maria Giulia
Tamberi, Stefano
Lonardi, Sara
Tonini, Giuseppe
Rosati, Gerardo
Latiano, Tiziana Pia
Tamburini, Emiliano
Maiello, Monica Rosaria
Carotenuto, Marianeve
Barone, Carlo
Pinto, Carmine
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[50] KRAS wild-type status in patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 regimen as the second/third-line setting: in comparison with the first-line setting
Wang, J. -Y.
Lin, S. -R.
VIRCHOWS ARCHIV, 2011, 459 : S22 - S22

← 1 2 3 4 5 →